Business Intelligence

Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.

Coming soon to a health system near you: ‘network radiology’

Radiology that facilitates the sharing of resources and touchpoints within an enterprise but across geographic locales is the future of the specialty, according to two Harvard radiology researchers.

FDA grants passage to autonomous, biology-guided radiotherapy

A therapeutic oncology company has been cleared to market a cancer treatment that that turns a tumor’s own biology into a self-signaling target for radiation therapy.

6 actions to help build a better workplace in the wake of the pandemic

Whatever specific shape work takes in the near and distant future, it’s likely the COVID-19 era will be looked back upon as a before-and-after dividing line.

FDA greenlights ultrasound MSK software with AI

Clarius Mobile Health of Vancouver, B.C., has won FDA approval to market an AI model that works with the company’s handheld point-of-care ultrasound devices to identify and measure tendons of the foot, ankle and knee.

Global survey finds radiology social-media users like YouTube best

Instagram is a fairly close second, Facebook a fighting third, Twitter a respectable fourth and LinkedIn a visible fifth.

CardiacSense, an Israel-based healthcare technology company, gained FDA clearance for its CSF-3 medical watch

Regulatory Roundup: FDA clears new medical watch, considers empagliflozin for CKD and much more

Our monthly review of FDA-related news items in the world of cardiology includes updates from CardiacSense, MedAlliance, Lupin, Realize Medical and Eli Lilly and Company. 

Portable orthopedic tomosynthesis cleared for U.S. sales

The FDA has cleared U.K.-based Adaptix to market a 3D X-ray system that, according to the company, images hands, feet and elbows “at a fraction of the radiation dose and per-study cost of traditional CT.”

Q4 and full-year 2022 results in for GE HealthCare

GE HealthCare has some favorable tailwinds at its back as it proceeds into its first year unattached to a certain venerable parent corporation.